NYSE American: IGC

Investor Relations

Committed to transparency and the advancement of next-generation therapies for neurodegenerative diseases through rigorous science and AI-driven innovation.

94_IGC-Pharma-Announces-Coverage-Report-by-Ascendiant-Capital-Markets-about-the-“Reports-Q3.
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts 
Read More →
93_IGC-Pharma-Adds-Tandem-Clinical-Research-to-the-CALMA-Trial-for-Agitation-in-Alzheimer’s-Disease
IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer’s Disease. 
Read More →
93_IGC-Pharma-Launches-Strategic-National-Media-Partnership-with-New-to-The-Street-to-Expand-Investor-Awareness-
IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness 
Read More →
91_IGC-Pharma-Reports-Financial-Results-and-Clinical-Progress-for-the-Transition-Period-Ended-December-31,-2025
IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025 
Read More →
90_IGC-Pharma-to-Showcase-AI-Platform-with-Alzheimer’s-Disease-Data-Initiative-at-ADPD-2026
IGC Pharma to Showcase AI Platform with Alzheimer’s Disease Data Initiative at ADPD 2026 
Read More →
Alzheimers-Patent-AI-Data-Research-Clinical-Trial
IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer’s Research 
Read More →
Alzheimers-Ascendiant-Capital-Market-Clinical-Trial
IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets 
Read More →
Alzheimers-Agitation-Visionary-Investigators Network-Clinical-Trial
IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial 
Read More →
86_Adds-Visionary-Investigators-Network-as-Clinical-Site-to-Phase-2-CALMA-Trial
IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances 
Read More →
85_IGC-Pharma-to-Participate-in-Fireside-Chat-with-Ascendiant-Capital-Marketspsb
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets 
Read More →
83_Announces-Equity-Research-Update-by-Alliance-Global-Partners
IGC Pharma Announces Equity Research Update by Alliance Global Partners 
Read More →
83_Expands-Phase-2-CALMA-Trial-into-Colombia-with-Leading-Alzheimer's-Research-Center
IGC Pharma Expands Phase 2 CALMA Trial into Colombia’s Premier Alzheimer’s Research Center 
Read More →
82_IGC-Pharma-Reports-70%-Patient-Enrollment-Milestone-in-Phase-2-CALMA-Alzheimer’s-Agitation-Trial- (1)
IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer’s Agitation 
Read More →
81_IGC-Pharma-Expands-Phase-2-CALMA-Trial-with-New-Clinical-Trail-Site-at-Integrative-Clinical-Trials-in-New-York_
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trail Site at Integrative Clinical Trials in New York 
Read More →
80_IGC-Pharma-Expands-Phase-2-CALMA-Trial-with-New-Clinical-Site-at-Dominion-Medical
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship network site, in Richmond, Virginia 
Read More →
79_IGC-Pharma-Aligns-Fiscal-Year-with-Calendar-Year-to-Enhance-U.S.-Investor-Comparability
IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability 
Read More →